Novo Nordisk A/S ADR buy BTIG Research
Start price
29.03.23
/
50%
€144.50
Target price
29.03.24
€28.58
Performance (%)
-16.96%
End price
30.03.24
€120.00
Summary
This prediction ended on 30.03.24 with a price of €120.00. The price of Novo Nordisk A/S ADR has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.96%. A total of €1.43 was paid as dividends for this prediction. BTIG_Research has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novo Nordisk A/S ADR | -2.467% | -2.467% | -15.150% | -76.534% |
| iShares Core DAX® | -1,59 % | 5,03 % | 6,33 % | 64,06 % |
| iShares Nasdaq 100 | -4,15 % | -0,13 % | 25,73 % | 86,92 % |
| iShares Nikkei 225® | -6,30 % | 0,53 % | 41,38 % | 77,87 % |
| iShares S&P 500 | -3,23 % | 0,47 % | 20,45 % | 68,19 % |
Comments by BTIG_Research for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE: NVO) had its price target raised by analysts at BTIG Research from $20.00 to $31.00. They now have a "buy" rating on the stock.
Ratings data for NVO provided by MarketBeat
In the thread Trading Novo Nordisk A/S ADR
Die von BTIG_Research gewählte maximale Laufzeit wurde überschritten